FEQ1 Stock Overview
A pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for FEQ1 from our risk checks.
Laboratorio Reig Jofre, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.75 |
| 52 Week High | €3.28 |
| 52 Week Low | €2.21 |
| Beta | 0.89 |
| 11 Month Change | -6.14% |
| 3 Month Change | 4.17% |
| 1 Year Change | 14.11% |
| 33 Year Change | -25.07% |
| 5 Year Change | 8.27% |
| Change since IPO | 22.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| FEQ1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.7% | -1.0% | 0.2% |
| 1Y | 14.1% | -19.3% | 8.5% |
Return vs Industry: FEQ1 exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: FEQ1 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| FEQ1 volatility | |
|---|---|
| FEQ1 Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: FEQ1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FEQ1's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 1,323 | Ignasi Reig | www.reigjofre.com |
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics. The company offers nutritional and parapharmacy products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women’s health; and food supplements under the Forté Pharma brand.
Laboratorio Reig Jofre, S.A. Fundamentals Summary
| FEQ1 fundamental statistics | |
|---|---|
| Market cap | €225.77m |
| Earnings (TTM) | €9.55m |
| Revenue (TTM) | €333.69m |
23.6x
P/E Ratio0.7x
P/S RatioIs FEQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FEQ1 income statement (TTM) | |
|---|---|
| Revenue | €333.69m |
| Cost of Revenue | €144.54m |
| Gross Profit | €189.15m |
| Other Expenses | €179.60m |
| Earnings | €9.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 56.68% |
| Net Profit Margin | 2.86% |
| Debt/Equity Ratio | 24.7% |
How did FEQ1 perform over the long term?
See historical performance and comparison